Lataa...
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow m...
Tallennettuna:
| Julkaisussa: | Front Immunol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6277686/ https://ncbi.nlm.nih.gov/pubmed/30538704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02749 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|